Linda Llewelyn Sells 6,442 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,442 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $7.88, for a total value of $50,762.96. Following the completion of the sale, the insider now owns 98,702 shares in the company, valued at approximately $777,771.76. The trade was a 6.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Linda Llewelyn also recently made the following trade(s):

• On Tuesday, October 15th, Linda Llewelyn sold 1,324 shares of Health Catalyst stock. The stock was sold at an average price of $8.16, for a total value of $10,803.84.

Health Catalyst Stock Down 4.1 %

Shares of NASDAQ HCAT opened at $6.97 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $424.11 million, a PE ratio of -5.16 and a beta of 1.31. The stock’s fifty day simple moving average is $8.13 and its two-hundred day simple moving average is $7.45. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period last year, the business posted ($0.22) EPS. As a group, analysts expect that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HCAT. Stephens increased their price target on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Royal Bank of Canada increased their price objective on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Evercore ISI increased their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Finally, Citigroup increased their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Health Catalyst has an average rating of “Moderate Buy” and a consensus target price of $11.79.

Institutional Trading of Health Catalyst

A number of institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. boosted its position in shares of Health Catalyst by 5.8% in the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock worth $857,000 after purchasing an additional 5,687 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Health Catalyst by 4.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after purchasing an additional 66,896 shares in the last quarter. Zacks Investment Management boosted its position in shares of Health Catalyst by 6.7% in the 3rd quarter. Zacks Investment Management now owns 296,121 shares of the company’s stock worth $2,410,000 after purchasing an additional 18,677 shares in the last quarter. State Street Corp boosted its position in shares of Health Catalyst by 2.5% in the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after purchasing an additional 28,251 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in shares of Health Catalyst in the 3rd quarter worth $84,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.